Owkin
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
Domain
owkin.com
Country
United StatesIndustry
Artificial Intelligence (AI)Employees
251-500
Last Funding
$50.0M
Founded
2015
Tech Stack (19 technologies)
Frequently Asked Questions
What technologies does Owkin use?+
Owkin uses 19 technologies including Cookiebot, Facebook Pixel, Google Analytics.
What industry is Owkin in?+
Owkin operates in the Artificial Intelligence (AI) industry.
Where is Owkin based?+
Owkin is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026